The heart and the gut

European Heart Journal

Volumn 35, Issue 7, 2014, Pages 426-430

  Rogler, Gerhard ^a   Rosano, Giuseppe ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Atherosclerosis; Bacterial translocation; Chronic heart failure; Intestinal barrier; Intestinal microbiome

Indexed keywords

ATHEROSCLEROSIS; BACTERIAL TRANSLOCATION; CHRONIC HEART FAILURE; INTESTINAL BARRIER; INTESTINAL MICROBIOME;

BACTERIAL PHYSIOLOGICAL PHENOMENA; DIGESTIVE SYSTEM; DIGESTIVE SYSTEM DISEASES; HEART DISEASES; HUMANS;

EID: 84894288139     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht271     Document Type: Review

References (90)

1. Holt S, Heading RC, Clements JA, Tothill P, Prescott LF. Acetaminophen absorption and metabolism in celiac disease and Crohn's disease. Clin Pharmacol Ther 1981;30: 232-238.
2. Lang CC, Brown RM, Kinirons MT, Deathridge MA, Guengerich FP, Kelleher D, O'Briain DS, Ghishan FK,Wood AJ. Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin Pharmacol Ther 1996;59:41-46.
3. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-490.
4. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009;10:1017-1024.
5. Sakurai E, HikichiN, Niwa H. Alteration of histamine, serotonin and primary prostaglandin in case of diarrhea induced by endotoxin and gastrointestinal absorption of drug. J Pharmacobiodyn 1985;8:186-192.
6. Melichar B, Dvorak J, Krcmova L, Hyspler R, Urbanek L, Solichova D. Intestinal permeability and vitaminAabsorption in patients with chemotherapy-induced diarrhea. Am J Clin Oncol 2008;31:580-584.
7. Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 2011;5:41-47.
8. Gandhi S, Narula N, Marshall JK, Farkouh M. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? Am J Med 2012;125:956-962.
9. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, Kastelein JJ, Stroes ES, de Groot E, Hommes DW. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007; 48:2640-2646.
10. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Jian M, Zhou Y, Li Y, Zhang X, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
11. Markowitz VM, Chen IM, Chu K, Szeto E, Palaniappan K, Jacob B, Ratner A, Liolios K, Pagani I, Huntemann M, Mavromatis K, Ivanova NN, Kyrpides NC. IMG/M-HMP: A metagenome comparative analysis system for the Human Microbiome Project. PLoS One 2012;7:e40151.
12. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-214.
13. Thompson AL. Developmental origins of obesity: early feeding environments, infant growth, and the intestinal microbiome. Am J Hum Biol 2012;24:350-360.
14. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci USA 2012;109:594-599.
15. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011;121:2126-2132.
16. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol 2010;26:5-11.
17. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009;587(Pt 17):4153-4158.
18. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
19. Fava F, Gitau R, Griffin BA, Gibson GR, Tuohy KM, Lovegrove JA. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes (Lond) 2013;37: 216-223.
20. Murgas Torrazza R, Neu J. The developing intestinal microbiome and its relationship to health and disease in the neonate. J Perinatol 2011;31(Suppl. 1):S29-S34.
21. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Murray PR, Turner ML, Segre JA. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850-859.
22. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrlander C, Heederik D, Piarroux R, von Mutius E. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364:701-709.
23. Cernadas M. It takes a microbiome: commensals, immune regulation, and allergy. Am J Respir Crit Care Med 2011;184:149-150.
24. Michail S, Durbin M, Turner D, Griffiths AM, Mack DR,Hyams J, Leleiko N, Kenche H, Stolfi A, Wine E. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 2012;18:1799-1808.
25. Zella GC, Hait EJ, Glavan T, Gevers D, Ward DV, Kitts CL, Korzenik JR. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis 2011;17:1092-1100.
26. Docktor MJ, Paster BJ, Abramowicz S, Ingram J, Wang YE, Correll M, Jiang H, Cotton SL, Kokaras AS, Bousvaros A. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012;18:935-942.
27. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010;139:1816-1819.
28. Li M,Wang B, Zhang M, Rantalainen M,Wang S, Zhou H, Zhang Y, Shen J, Pang X, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao L. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008;105: 2117-2122.
29. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-323.
30. Flier JS, Mekalanos JJ. Gut check: testing a role for the intestinal microbiome in human obesity. Sci Transl Med 2009;1:6ps7.
31. Tsai F, Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep 2009;11:307-313.
32. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008;3:213-223.
33. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009;1:6ra14.
34. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
35. Valtonen VV. Infection as a risk factor for infarction and atherosclerosis. Ann Med 1991;23:539-543.
36. Costales P, Castellano J, Revuelta-Lopez E, Cal R, Aledo R, Llampayas O, Nasarre L, Juarez C, Badimon L, Llorente-Cortes V. Lipopolysaccharide downregulates CD91/low-density lipoprotein receptor-related protein 1 expression through SREBP-1 overexpression in human macrophages. Atherosclerosis 2013;227:79-88.
37. Wiesner P, Choi SH, Almazan F, Benner C, HuangW, Diehl CJ, Gonen A, Butler S, Witztum JL, Glass CK, Miller YI. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res 2010;107:56-65.
38. Feng X, Zhang Y,Xu R, Xie X, Tao L, Gao H, Gao Y, He Z,Wang H. Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis 2010;208:396-405.
39. Maziere C, Conte MA, Dantin F, Maziere JC. Lipopolysaccharide enhances oxidative modification of low density lipoprotein by copper ions, endothelial and smooth muscle cells. Atherosclerosis 1999;143:75-80.
40. Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss LK. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 1994;14:790-797.
41. Zhao Y, Cui G, Zhang N, Liu Z, SunW, Peng Q. Lipopolysaccharide induces endothelial cell apoptosis via activation of Na(+)/H(+) exchanger 1 and calpaindependent degradation of Bcl-2. Biochem Biophys Res Commun 2012;427:125-132.
42. Yang Y, Li Q, Deng Z, Zhang Z, Xu J, Qian G, Wang G. Protection from lipopolysaccharide-induced pulmonary microvascular endothelial cell injury by activation of hedgehog signaling pathway. Mol Biol Rep 2011;38:3615-3622.
43. Koide N, Morikawa A, Tumurkhuu G, Dagvadorj J, Hassan F, Islam S, Naiki Y, Mori I, Yoshida T, Yokochi T. Lipopolysaccharide and interferon-gamma enhance Fasmediated cell death in mouse vascular endothelial cells via augmentation of Fas expression. Clin Exp Immunol 2007;150:553-560.
44. Konter JM, Parker JL, Baez E, Li SZ, Ranscht B, Denzel M, Little FF, Nakamura K, Ouchi N, Fine A, Walsh K, Summer RS. Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J Immunol 2012;188:854-863.
45. Dayoub JC, Ortiz F, Lopez LC, Venegas C, Del Pino-Zumaquero A, Roda O, Sanchez-Montesinos I, Acuna-Castroviejo D, Escames G. Synergismbetween melatonin and atorvastatin against endothelial celldamage induced by lipopolysaccharide. J Pineal Res 2011;51:324-330.
46. Morel DW, DiCorleto PE, Chisolm GM. Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. Lab Invest 1986;55:419-426.
47. HowellKW, Meng X, Fullerton DA, Jin C, Reece TB, Cleveland JC Jr. Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J Surg Res 2011;171:e27-e31.
48. Pataki M, Lusztig G, Robenek H. Endocytosis of oxidized LDL and reversibility of migration inhibition in macrophage-derived foam cells in vitro.Amechanism for atherosclerosis regression? Arterioscler Thromb 1992;12:936-944.
49. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999;34:1975-1981.
50. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-192.
51. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP. Toll-like receptormediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor gamma coactivator-1 signaling. Circ Heart Fail 2011;4:474-482.
52. Avlas O, Fallach R, Shainberg A, Porat E, Hochhauser E. Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility. Antioxid Redox Signal 2011;15:1895-1909.
53. Fallach R, Shainberg A,Avlas O, Fainblut M, ChepurkoY, Porat E, Hochhauser E. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol 2010;48:1236-1244.
54. Boyd JH, Mathur S,Wang Y, Bateman RM,Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006;72:384-393.
55. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzman NH, Baker JE. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012;26:1727-1735.
56. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-436.
57. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996;348(Suppl. 1): s13-s17.
58. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, SeymourCA,CammAJ. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311:711-714.
59. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2: 983-986.
60. Khan S, Okamoto T, Enomoto K, Sakashita N, Oyama K, Fujii S, Sawa T, Takeya M, Ogawa H, Yamabe H, Akaike T. Potential association of Helicobacter cinaedi with atrial arrhythmias and atherosclerosis. Microbiol Immunol 2012;56:145-154.
61. DoreMP, Sepulveda AR, Bacciu PP, Blasi F, Simula L, Marras L, Piccolo D,Cherchi GB, Graham DY, Realdi G. Detection of Chlamydiae pneumoniae but not Helicobacter pylori DNA in atherosclerosis plaques. Dig Dis Sci 2003;48:945-951.
62. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000;102:833-839.
63. Sessa R, Nicoletti M, Di Pietro M, Schiavoni G, Santino I, Zagaglia C, Del Piano M, Cipriani P. Chlamydia pneumoniae and atherosclerosis: current state and future prospectives. Int J Immunopathol Pharmacol 2009;22:9-14.
64. Fazio G, Giovino M, Gullotti A, Bacarella D, Novo G, Novo S. Atherosclerosis, inflammation and Chlamydia pneumoniae. World J Cardiol 2009;1:31-40.
65. Campbell LA, Kuo CC. Chlamydia pneumonia-an infectious risk factor for atherosclerosis? Nat Rev Microbiol 2004;2:23-32.
66. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106:1219-1223.
67. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997;350:404-407.
68. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290:1459-1466.
69. Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol 2008;125:240-245.
70. Sandek A, Anker SD, von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab 2009;10:22-28.
71. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care 2008;11:632-639.
72. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1561-1569.
73. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005;26:2368-2374.
74. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:1426-1430.
75. Chong AJ, Shimamoto A,Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004;128:170-179.
76. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, Kubes P. Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 2004;95:700-707.
77. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-1486.
78. Rauchhaus M, DoehnerW, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-3067.
79. Kumar A, Krieger A, Symeoneides S, Parrillo JE. Myocardial dysfunction in septic shock. Part II: Role of cytokines and nitric oxide. J Cardiothorac Vasc Anesth 2001; 15:485-511.
80. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock. Part I: Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth 2001;15: 364-376.
81. Muller-Werdan U, Engelmann H,Werdan K. Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 1998;9:689-691.
82. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004;90:464-470.
83. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, Schulz R. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003;57:426-433.
84. Sharma R, Bolger AP, Rauchhaus M, von Haehling S, Doehner W, Adcock IM, Barnes PJ, Poole-Wilson PA, VolkHD, Coats AJ, Lim S, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail 2005;7: 865-868.
85. Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR,Wensel R, Coats AJ, Anker SD. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 2002; 90:1226-1230.
86. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003;5:609-614.
87. Gutierrez G, Palizas F, Doglio G, Pusajo J, Wainsztein N, Klein F, Gallesio A, San Roman E, Pacin J, Dorfman B, Dubin A, Schiavi E, Shottender J, Jorge M, Giniger R. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992;339:195-199.
88. Maynard N, Bihari D, Beale R, Smithies M, Baldock G, Mason R, McColl I. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA 1993;270:1203-1210.
89. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007;449:721-725.
90. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-1842.